Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Sintilimab + Chidamide in Refractory MSS Metastatic Colorectal Cancer
NCT06979908Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, sintilimab, tucidinostat in metastatic colorectal cancer (mCRC), sponsored by The First Hospital of Jilin University. Started Jan 2025; status: recruiting.
02
Drugs
fruquintinibsintilimabtucidinostat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06979908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979908.